⌘K
Loading ticker…
As of 2026-08-24, AYTU BioPharma, Inc. Common Stock (AYTU) has a 3-month relative strength percentile of 59 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 51. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 3.8%, relative volume 0.48×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
AYTU is in a stage 1 base, week 4. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: 3.8% / -2.7%.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
AYTU is held by 4 ETFs as of Apr 2026. Top owner: DFSU at 0.00% weight, $12K notional. Top 3 carry $34K.
Held by 6 ETFs · $723K across latest filings · largest weight 0.00% (DFSU).
Top 4 by value, from SEC N-PORT-P filings dated Apr 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| DFSU | 0.00% | $12K | — |
| DFASDimensional U.S. Small Cap ETF | 0.00% | $11K | — |
| DFACDimensional U.S. Core Equity 2 ETF | 0.00% | $11K | new |
| DCOR | 0.00% | $6K | — |
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Weak relative strength and quiet attention. Little to read here either way.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
Daily range, ATR, beta, and the math for a 1-ADR stop.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | AYTU Jan avg: -4.66% median: -2.97% win: 0% σ: 5.59% n: 4 2022-04-12 → 2026-07-31 | AYTU Feb avg: -9.30% median: -10.27% win: 25% σ: 13.82% n: 4 2022-04-12 → 2026-07-31 | AYTU Mar avg: -2.84% median: -0.89% win: 50% σ: 10.51% n: 4 2022-04-12 → 2026-07-31 | AYTU Apr avg: -5.05% median: -5.50% win: 40% σ: 15.95% n: 5 2022-04-12 → 2026-07-31 | AYTU May avg: -2.32% median: -11.24% win: 40% σ: 24.16% n: 5 2022-04-12 → 2026-07-31 | AYTU Jun avg: 6.26% median: -4.19% win: 40% σ: 16.71% n: 5 2022-04-12 → 2026-07-31 | AYTU Jul avg: -1.02% median: 3.72% win: 60% σ: 15.93% n: 5 2022-04-12 → 2026-07-31 | AYTU Aug avg: -18.16% median: -5.87% win: 0% σ: 26.06% n: 4 2022-04-12 → 2026-07-31 (current) | AYTU Sep avg: 3.99% median: -11.43% win: 25% σ: 37.04% n: 4 2022-04-12 → 2026-07-31 | AYTU Oct avg: -1.93% median: -5.08% win: 50% σ: 17.13% n: 4 2022-04-12 → 2026-07-31 | AYTU Nov avg: -2.70% median: -9.84% win: 25% σ: 19.44% n: 4 2022-04-12 → 2026-07-31 | AYTU Dec avg: 10.12% median: 12.16% win: 75% σ: 14.27% n: 4 2022-04-12 → 2026-07-31 |